Monash IVF Group（MNIV.F）株式概要モナシュIVFグループ・リミテッドは、オーストラリアとマレーシアで生殖補助医療と女性専門画像診断サービスを提供しています。 詳細MNIV.F ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長0/6過去の実績2/6財務の健全性2/6配当金3/6報酬当社が推定した公正価値より72.6%で取引されている 今年は黒字化を達成 リスク分析株式の流動性は非常に低い 今後3年間の収益は年平均0.1%減少すると予測されている。 7.48%の配当はフリーキャッシュフローで十分にカバーされていない すべてのリスクチェックを見るMNIV.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.408.1% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-7m307m2016201920222025202620282031Revenue AU$306.9mEarnings AU$28.2mAdvancedSet Fair ValueView all narrativesMonash IVF Group Limited 競合他社AunaSymbol: NYSE:AUNAMarket cap: US$319.0mCommunity Health SystemsSymbol: NYSE:CYHMarket cap: US$379.3mJointSymbol: NasdaqCM:JYNTMarket cap: US$122.6mU.S. Physical TherapySymbol: NYSE:USPHMarket cap: US$943.0m価格と性能株価の高値、安値、推移の概要Monash IVF Group過去の株価現在の株価AU$0.4052週高値AU$0.7452週安値AU$0.40ベータ0.731ヶ月の変化0%3ヶ月変化n/a1年変化n/a3年間の変化n/a5年間の変化n/aIPOからの変化-45.95%最新ニュースお知らせ • Apr 20WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF).WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.85 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. As of April 13, 2026 Monash IVF Group Limited has now received a revised, unsolicited, conditional and non-binding indicative proposal from WHSP Holdings Limited (ASX:SOL) and Genesis Capital. The indicative cash price offered to shareholders under the Proposal is AUD 0.90 per share. As part part of consideration AUD 281.93 million is paid towards common equity and AUD 1.68 million is paid towards performance rights. It should be noted that there is no certainty that the discussions with the Consortium will result in any transaction. If there are material developments in the future, Monash IVF will inform shareholders as required under its continuous disclosure obligations. The deal is conditional upon exclusive due diligence, including a 4-week period of exclusivity with no fiduciary exceptions, negotiation and execution of transaction documentation on 'customary terms', including a no material adverse change condition, unanimous recommendation of the Monash IVF Board of the Proposal and final internal approval from the relevant Consortium Members for a final binding proposal and entry into transaction documentation. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF) on April 20, 2026. Monash IVF Group Limited announced that its Board has unanimously rejected the revised non-binding proposal from Genesis Capital and Soul Patts to acquire the company for AUD 0.90 per share, stating the offer undervalues the company but remains open to a higher bid. This captures the rejection, the offer price, the reason, and the fact that the door remains open for a higher offer, which are the key takeaways for our tracking purposes.お知らせ • Feb 26Monash IVF Group Limited Announces Ordinary Fully Franked Interim Dividend for the Period Ended December 31, 2025, Payable on 10 April 2026Monash IVF Group Limited announced ordinary fully franked interim dividend of AUD 0.01200000 per share for the period ended December 31, 2025. The record date for the dividend is 5 March 2026 and the payment date is 10 April 2026. Ex date is March 4, 2026.お知らせ • Jan 27+ 1 more updateMonash IVF Group Limited Announces Resignation of Malik Jainudeen as Company Secretary, Effective End of April 2026Monash IVF Group Limited announced the resignation of Company Secretary, Mr. Malik Jainudeen. Mr. Jainudeen will remain with Monash IVF Group until the end of April 2026 before he commences his new role at another organisation. Malik Jainudeen has made significant contributions since joining Monash IVF Group in 2014, including stepping into the Acting CEO role during the last six months.お知らせ • Jan 23Monash IVF Group Limited to Report Fiscal Year 2026 Results on Aug 24, 2026Monash IVF Group Limited announced that they will report fiscal year 2026 results on Aug 24, 2026お知らせ • Jan 20Monash IVF Group Limited to Report First Half, 2026 Results on Feb 26, 2026Monash IVF Group Limited announced that they will report first half, 2026 results on Feb 26, 2026お知らせ • Nov 24WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million.WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.8 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) on November 24, 2025.最新情報をもっと見るRecent updatesお知らせ • Apr 20WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF).WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.85 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. As of April 13, 2026 Monash IVF Group Limited has now received a revised, unsolicited, conditional and non-binding indicative proposal from WHSP Holdings Limited (ASX:SOL) and Genesis Capital. The indicative cash price offered to shareholders under the Proposal is AUD 0.90 per share. As part part of consideration AUD 281.93 million is paid towards common equity and AUD 1.68 million is paid towards performance rights. It should be noted that there is no certainty that the discussions with the Consortium will result in any transaction. If there are material developments in the future, Monash IVF will inform shareholders as required under its continuous disclosure obligations. The deal is conditional upon exclusive due diligence, including a 4-week period of exclusivity with no fiduciary exceptions, negotiation and execution of transaction documentation on 'customary terms', including a no material adverse change condition, unanimous recommendation of the Monash IVF Board of the Proposal and final internal approval from the relevant Consortium Members for a final binding proposal and entry into transaction documentation. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF) on April 20, 2026. Monash IVF Group Limited announced that its Board has unanimously rejected the revised non-binding proposal from Genesis Capital and Soul Patts to acquire the company for AUD 0.90 per share, stating the offer undervalues the company but remains open to a higher bid. This captures the rejection, the offer price, the reason, and the fact that the door remains open for a higher offer, which are the key takeaways for our tracking purposes.お知らせ • Feb 26Monash IVF Group Limited Announces Ordinary Fully Franked Interim Dividend for the Period Ended December 31, 2025, Payable on 10 April 2026Monash IVF Group Limited announced ordinary fully franked interim dividend of AUD 0.01200000 per share for the period ended December 31, 2025. The record date for the dividend is 5 March 2026 and the payment date is 10 April 2026. Ex date is March 4, 2026.お知らせ • Jan 27+ 1 more updateMonash IVF Group Limited Announces Resignation of Malik Jainudeen as Company Secretary, Effective End of April 2026Monash IVF Group Limited announced the resignation of Company Secretary, Mr. Malik Jainudeen. Mr. Jainudeen will remain with Monash IVF Group until the end of April 2026 before he commences his new role at another organisation. Malik Jainudeen has made significant contributions since joining Monash IVF Group in 2014, including stepping into the Acting CEO role during the last six months.お知らせ • Jan 23Monash IVF Group Limited to Report Fiscal Year 2026 Results on Aug 24, 2026Monash IVF Group Limited announced that they will report fiscal year 2026 results on Aug 24, 2026お知らせ • Jan 20Monash IVF Group Limited to Report First Half, 2026 Results on Feb 26, 2026Monash IVF Group Limited announced that they will report first half, 2026 results on Feb 26, 2026お知らせ • Nov 24WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million.WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.8 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) on November 24, 2025.お知らせ • Oct 20Monash IVF Group Limited, Annual General Meeting, Nov 20, 2025Monash IVF Group Limited, Annual General Meeting, Nov 20, 2025. Location: kpmg tower two, level 36, meeting room 36.17, collins square, 727 collins street, melbourne vic 3008 Australiaお知らせ • Jun 12+ 1 more updateMonash IVF Group Limited Announces CEO ChangesMonash IVF Group Limited's Board has on June 12, 2025 accepted Michael Knaap's resignation as Chief Executive Officer of the company. Since his appointment in 2019, Michael has led the organisation through a period of significant growth and transformation, and The company thanks him for his years of dedicated service. Monash IVF Group Chief Financial Officer and Company Secretary, Malik Jainudeen has been appointed as Acting Chief Executive Officer. Malik Jainudeen brings over a decade of service to Monash IVF Group, having joined in 2014 and serving as Chief Financial Officer and Company Secretary since 2019. His deep understanding of the organisation's operations, positions him as a steady and capable leader during this transitional period. With a background that includes ten years at KPMG managing audits for major ASX-listed companies, Malik combines financial understanding with a comprehensive knowledge of the healthcare sector.お知らせ • Mar 01Monash IVF Group Limited Declares Fully Franked Interim Dividend for the First Half ended 31 December 2024, Payable on 11 April 2025Monash IVF Group Limited declared fully franked interim dividend for the first half ended 31 December 2024 of 2.6 cents per share. The record date for the dividend is 7 March 2025 and the payment date is 11 April 2025.株主還元MNIV.FUS HealthcareUS 市場7D0%-0.4%1.1%1Yn/a16.3%28.7%株主還元を見る業界別リターン: MNIV.FがUS Healthcare業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: MNIV.F US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is MNIV.F's price volatile compared to industry and market?MNIV.F volatilityMNIV.F Average Weekly Movementn/aHealthcare Industry Average Movement7.6%Market Average Movement7.2%10% most volatile stocks in US Market16.5%10% least volatile stocks in US Market3.1%安定した株価: MNIV.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のMNIV.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2014892Malik Jainudeenwww.monashivfgroup.com.auモナシュIVFグループ・リミテッドは、オーストラリアとマレーシアで生殖補助医療と女性専門画像診断サービスを提供している。同社は産科診断、婦人科超音波診断、不妊治療サービスを提供している。また、三次レベルの出生前診断、体外受精治療サービスも提供している。モナシュIVFグループ・リミテッドは2014年に法人化され、オーストラリアのクレモーンに拠点を置く。もっと見るMonash IVF Group Limited 基礎のまとめMonash IVF Group の収益と売上を時価総額と比較するとどうか。MNIV.F 基礎統計学時価総額US$177.42m収益（TTM）US$16.38m売上高(TTM)US$178.15m10.8xPER（株価収益率1.0xP/SレシオMNIV.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計MNIV.F 損益計算書（TTM）収益AU$271.92m売上原価AU$181.60m売上総利益AU$90.31mその他の費用AU$65.31m収益AU$25.01m直近の収益報告Jun 30, 2025次回決算日該当なし一株当たり利益（EPS）0.064グロス・マージン33.21%純利益率9.20%有利子負債／自己資本比率39.5%MNIV.F の長期的なパフォーマンスは？過去の実績と比較を見る配当金7.5%現在の配当利回り41%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/09/06 04:05終値2025/06/10 00:00収益2025/06/30年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Monash IVF Group Limited 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。14 アナリスト機関Martyn JacobsBell PotterBradley WatsonBell PotterTara SperanzaBell Potter11 その他のアナリストを表示
お知らせ • Apr 20WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF).WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.85 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. As of April 13, 2026 Monash IVF Group Limited has now received a revised, unsolicited, conditional and non-binding indicative proposal from WHSP Holdings Limited (ASX:SOL) and Genesis Capital. The indicative cash price offered to shareholders under the Proposal is AUD 0.90 per share. As part part of consideration AUD 281.93 million is paid towards common equity and AUD 1.68 million is paid towards performance rights. It should be noted that there is no certainty that the discussions with the Consortium will result in any transaction. If there are material developments in the future, Monash IVF will inform shareholders as required under its continuous disclosure obligations. The deal is conditional upon exclusive due diligence, including a 4-week period of exclusivity with no fiduciary exceptions, negotiation and execution of transaction documentation on 'customary terms', including a no material adverse change condition, unanimous recommendation of the Monash IVF Board of the Proposal and final internal approval from the relevant Consortium Members for a final binding proposal and entry into transaction documentation. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF) on April 20, 2026. Monash IVF Group Limited announced that its Board has unanimously rejected the revised non-binding proposal from Genesis Capital and Soul Patts to acquire the company for AUD 0.90 per share, stating the offer undervalues the company but remains open to a higher bid. This captures the rejection, the offer price, the reason, and the fact that the door remains open for a higher offer, which are the key takeaways for our tracking purposes.
お知らせ • Feb 26Monash IVF Group Limited Announces Ordinary Fully Franked Interim Dividend for the Period Ended December 31, 2025, Payable on 10 April 2026Monash IVF Group Limited announced ordinary fully franked interim dividend of AUD 0.01200000 per share for the period ended December 31, 2025. The record date for the dividend is 5 March 2026 and the payment date is 10 April 2026. Ex date is March 4, 2026.
お知らせ • Jan 27+ 1 more updateMonash IVF Group Limited Announces Resignation of Malik Jainudeen as Company Secretary, Effective End of April 2026Monash IVF Group Limited announced the resignation of Company Secretary, Mr. Malik Jainudeen. Mr. Jainudeen will remain with Monash IVF Group until the end of April 2026 before he commences his new role at another organisation. Malik Jainudeen has made significant contributions since joining Monash IVF Group in 2014, including stepping into the Acting CEO role during the last six months.
お知らせ • Jan 23Monash IVF Group Limited to Report Fiscal Year 2026 Results on Aug 24, 2026Monash IVF Group Limited announced that they will report fiscal year 2026 results on Aug 24, 2026
お知らせ • Jan 20Monash IVF Group Limited to Report First Half, 2026 Results on Feb 26, 2026Monash IVF Group Limited announced that they will report first half, 2026 results on Feb 26, 2026
お知らせ • Nov 24WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million.WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.8 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) on November 24, 2025.
お知らせ • Apr 20WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF).WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.85 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. As of April 13, 2026 Monash IVF Group Limited has now received a revised, unsolicited, conditional and non-binding indicative proposal from WHSP Holdings Limited (ASX:SOL) and Genesis Capital. The indicative cash price offered to shareholders under the Proposal is AUD 0.90 per share. As part part of consideration AUD 281.93 million is paid towards common equity and AUD 1.68 million is paid towards performance rights. It should be noted that there is no certainty that the discussions with the Consortium will result in any transaction. If there are material developments in the future, Monash IVF will inform shareholders as required under its continuous disclosure obligations. The deal is conditional upon exclusive due diligence, including a 4-week period of exclusivity with no fiduciary exceptions, negotiation and execution of transaction documentation on 'customary terms', including a no material adverse change condition, unanimous recommendation of the Monash IVF Board of the Proposal and final internal approval from the relevant Consortium Members for a final binding proposal and entry into transaction documentation. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF) on April 20, 2026. Monash IVF Group Limited announced that its Board has unanimously rejected the revised non-binding proposal from Genesis Capital and Soul Patts to acquire the company for AUD 0.90 per share, stating the offer undervalues the company but remains open to a higher bid. This captures the rejection, the offer price, the reason, and the fact that the door remains open for a higher offer, which are the key takeaways for our tracking purposes.
お知らせ • Feb 26Monash IVF Group Limited Announces Ordinary Fully Franked Interim Dividend for the Period Ended December 31, 2025, Payable on 10 April 2026Monash IVF Group Limited announced ordinary fully franked interim dividend of AUD 0.01200000 per share for the period ended December 31, 2025. The record date for the dividend is 5 March 2026 and the payment date is 10 April 2026. Ex date is March 4, 2026.
お知らせ • Jan 27+ 1 more updateMonash IVF Group Limited Announces Resignation of Malik Jainudeen as Company Secretary, Effective End of April 2026Monash IVF Group Limited announced the resignation of Company Secretary, Mr. Malik Jainudeen. Mr. Jainudeen will remain with Monash IVF Group until the end of April 2026 before he commences his new role at another organisation. Malik Jainudeen has made significant contributions since joining Monash IVF Group in 2014, including stepping into the Acting CEO role during the last six months.
お知らせ • Jan 23Monash IVF Group Limited to Report Fiscal Year 2026 Results on Aug 24, 2026Monash IVF Group Limited announced that they will report fiscal year 2026 results on Aug 24, 2026
お知らせ • Jan 20Monash IVF Group Limited to Report First Half, 2026 Results on Feb 26, 2026Monash IVF Group Limited announced that they will report first half, 2026 results on Feb 26, 2026
お知らせ • Nov 24WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million.WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.8 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) on November 24, 2025.
お知らせ • Oct 20Monash IVF Group Limited, Annual General Meeting, Nov 20, 2025Monash IVF Group Limited, Annual General Meeting, Nov 20, 2025. Location: kpmg tower two, level 36, meeting room 36.17, collins square, 727 collins street, melbourne vic 3008 Australia
お知らせ • Jun 12+ 1 more updateMonash IVF Group Limited Announces CEO ChangesMonash IVF Group Limited's Board has on June 12, 2025 accepted Michael Knaap's resignation as Chief Executive Officer of the company. Since his appointment in 2019, Michael has led the organisation through a period of significant growth and transformation, and The company thanks him for his years of dedicated service. Monash IVF Group Chief Financial Officer and Company Secretary, Malik Jainudeen has been appointed as Acting Chief Executive Officer. Malik Jainudeen brings over a decade of service to Monash IVF Group, having joined in 2014 and serving as Chief Financial Officer and Company Secretary since 2019. His deep understanding of the organisation's operations, positions him as a steady and capable leader during this transitional period. With a background that includes ten years at KPMG managing audits for major ASX-listed companies, Malik combines financial understanding with a comprehensive knowledge of the healthcare sector.
お知らせ • Mar 01Monash IVF Group Limited Declares Fully Franked Interim Dividend for the First Half ended 31 December 2024, Payable on 11 April 2025Monash IVF Group Limited declared fully franked interim dividend for the first half ended 31 December 2024 of 2.6 cents per share. The record date for the dividend is 7 March 2025 and the payment date is 11 April 2025.
